Filing Flows › Endovia Health Sciences (EDVA) › Q4 2024
Endovia Health Sciences (EDVA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Jul 11, 2025
Endovia Health Sciences (EDVA) reported revenue of $586K for the fourth quarter 2024 (Q4 2024), -78% from a year earlier and -40% from the quarter before.
Endovia Health Sciences, Q4 2024: revenue $586K (-78% year over year), net loss $9.0M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $586K | -40% | -78% |
| Operating profit | −$6.4M | — | — |
| Net earnings | −$9.0M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $586K in Q4 2024, down 78% year over year and down 40% from the previous quarter.
Operating costs exceeded revenue by $6.4M, an operating margin of -1098.4%. The fastest-growing cost line was Other operating costs (+65%). The quarter ended with a net loss of $9.0M, wider than the previous quarter's $4.7M loss.
Operating cash flow was −$1.6M. Non-cash charges added back $135K of depreciation and amortization and $265K of share-based compensation. Working capital and other items added $7.0M.
Questions
What was Endovia Health Sciences' revenue in the fourth quarter 2024?
Endovia Health Sciences (EDVA) reported revenue of $586K for the fourth quarter 2024 (Q4 2024), -78% from a year earlier and -40% from the quarter before.